HC Wainwright Predicts Krystal Biotech Q1 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Krystal Biotech in a note issued to investors on Wednesday, February 19th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of $1.56 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $221.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q2 2025 earnings at $1.74 EPS, Q3 2025 earnings at $1.98 EPS, Q4 2025 earnings at $2.24 EPS, FY2025 earnings at $6.97 EPS, FY2026 earnings at $6.23 EPS, FY2027 earnings at $8.49 EPS and FY2028 earnings at $8.78 EPS.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the previous year, the business posted $0.30 earnings per share. The company’s revenue was up 116.4% on a year-over-year basis.

KRYS has been the subject of several other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday. Citigroup upped their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday. Finally, Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $210.00.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $187.86 on Monday. Krystal Biotech has a one year low of $107.50 and a one year high of $219.34. The company has a 50 day moving average price of $157.85 and a 200 day moving average price of $175.26. The firm has a market capitalization of $5.41 billion, a price-to-earnings ratio of 62.83 and a beta of 0.84.

Institutional Investors Weigh In On Krystal Biotech

Several large investors have recently made changes to their positions in the business. US Bancorp DE increased its position in shares of Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after acquiring an additional 82 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company’s stock valued at $407,000 after purchasing an additional 82 shares during the period. Crossmark Global Holdings Inc. boosted its stake in shares of Krystal Biotech by 5.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after purchasing an additional 121 shares during the period. Envestnet Asset Management Inc. boosted its stake in shares of Krystal Biotech by 1.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company’s stock valued at $1,822,000 after purchasing an additional 121 shares during the period. Finally, Perigon Wealth Management LLC boosted its stake in shares of Krystal Biotech by 1.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock valued at $1,200,000 after purchasing an additional 123 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).